99: How Fat Hormones Affect Appetite, Inflammation, and Heart Health with Dr. Ben Bikman

Bikman explains that obesity, particularly visceral obesity, creates a hormonal milieu that promotes insulin resistance and clotting. Adiponectin, which breaks down ceramides to maintain insulin sensitivity, falls in obesity; PAI-1, which blocks clot dissolution, rises. Weight loss reverses these changes, restoring metabolic and cardiovascular protections. This is why even modest weight loss yields substantial reductions in diabetes and heart disease risk, independent of other risk factors.

Bikman references a 2014 JCI study showing that cold-activated brown fat dramatically increases T3, potentially becoming the primary source of active thyroid hormone in the body. This not only drives thermogenesis but also supports whole-body metabolic processes. He posits that this may explain why cold exposure has been linked to improved glycemic control and weight loss.

Bikman explains that while leptin does provide a subtle, long-term appetite signal by informing the brain of energy stores, it is not the primary meal-by-meal stop signal like GLP-1. When body fat falls too low, leptin levels drop, depriving the brain of the signal needed to maintain reproductive function. In women, this leads to halted ovulation and amenorrhea; in men, reduced testosterone and impaired sperm production. Humans with leptin mutations become obese but are invariably infertile, and leptin-deficient mice cannot breed if homozygous. This evidence suggests leptin’s reproductive function is its most essential evolved role, and he would rewrite endocrinology textbooks accordingly.

Bikman details that ceramides accumulate inside cells and block the insulin signal, causing insulin resistance. Adiponectin, produced by fat cells, activates the enzyme ceramidase, which breaks down ceramides, thereby removing the blockade. In obesity, fat tissue expands but secretes less adiponectin, so ceramides rise and insulin resistance worsens. Adiponectin also has anti-inflammatory effects and promotes fat burning, helping prevent ectopic lipid deposition in liver and pancreas. Weight loss, especially visceral fat loss, can boost adiponectin, reinstating these protections.

PAI-1 blocks tissue plasminogen activator (TPA), the enzyme that dissolves blood clots. High PAI-1 makes clots linger and promotes thrombosis. Visceral fat is a major source of PAI-1 production, and its levels rise with visceral obesity. This explains why central obesity sharply elevates heart attack and stroke risk. Weight loss, particularly of visceral fat, lowers PAI-1, reducing clotting tendency. Bikman references a 2003 study by Alessi et al. that established this link.

Brown fat expresses high levels of the enzyme that converts the prohormone T4 into active T3. When cold exposure activates brown fat, this conversion ramps up dramatically. A 2014 study by De Jesus and colleagues in JCI demonstrated that cold-activated brown fat can significantly increase circulating T3, potentially becoming the main source of T3 in the body under those conditions. This links thermogenesis directly to thyroid function, suggesting that strategies to activate brown fat could improve metabolic rate and energy expenditure through local T3 production.

Subcutaneous fat produces higher leptin and adiponectin and lower pro-inflammatory cytokines, supporting metabolic health. Visceral fat churns out PAI-1, resistin, TNF-alpha, angiotensinogen—driving insulin resistance, inflammation, clotting, and hypertension. Brown fat secretes FGF-21 and facilitates T3 conversion, enhancing fat burning and insulin sensitivity. Thus, two individuals with identical total fat mass can have vastly different risks depending on where the fat sits, explaining the ‘metabolically healthy obese’ phenomenon and the danger of central obesity.

TNF-alpha is a well-known pro-inflammatory cytokine; its production by fat tissue, especially visceral, links obesity to chronic inflammation. This inflammation then drives insulin resistance, atherosclerosis, and other metabolic disruptions. For Bikman, the realization that fat is not inert but actively secretes inflammatory signals changed his perspective and motivated his research. He cites the Hotamisligil group paper as the catalyst.